Higher triglycerides levels may lower risk of dementia in older adults

Written By :  Dr. Kamal Kant Kohli
Published On 2023-10-29 11:30 GMT   |   Update On 2023-10-29 11:30 GMT

Australia: Older adults with higher triglyceride levels are at a lower risk of dementia and slower cognitive decline over time compared to individuals with lower triglyceride levels, a recent study published in Neurology has revealed. 

"Higher levels of triglyceride, a type of fat, may be reflective of better overall health and lifestyle behaviours that would protect against the development of dementia," the study stated. While the study found a link, it does not prove that higher levels of triglycerides prevent dementia.

Triglycerides are fatty acids and are the most common type of fat in the blood. Triglycerides contribute up to 95% of dietary fats, which are the main energy source of the brain.

“Higher triglyceride levels may be reflective of better overall health and lifestyle behaviours that would protect against dementia,” said study author Zhen Zhou, PhD, of Monash University in Melbourne, Australia. “Our findings suggest that triglyceride levels may serve as a useful predictor for dementia risk and cognitive decline in older populations.”

Researchers used healthcare data to identify 18,294 people in one cohort with an average age of 75 who did not have a prior diagnosis of Alzheimer’s disease or dementia.

Participants were followed for an average of six years. During that time, 823 people developed dementia.

Researchers looked at participants’ measurements of total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL) and high-density lipoprotein cholesterol (HDL) each year of the study.

Then researchers divided participants into four groups based on fasting triglyceride levels. Of the total group, average triglycerides were 106 milligrams per deciliter (mg/dL). For adults, a normal or healthy triglyceride level is below 150 mg/dL.

After adjusting for variables that could affect risk of dementia including education and cholesterol-lowering treatments, researchers found every doubling of triglyceride levels was associated with an 18% lower risk of developing dementia.

The lowest triglyceride group had levels of less than 62 mg/dL. The second group had levels of 63 to 106 mg/dL. Compared to the lowest group, the second group was 15% less likely to develop dementia. The third group had levels of 107 to 186 mg/dL. Compared to the lowest group, they were 24% less likely to develop dementia. The fourth group had levels of 187 mg/dL or higher. Compared to the lowest group, they were 36% less likely to develop dementia.

Of the 1,416 people in the lowest triglyceride group, 82 people, or 6%, developed dementia. Of the 7,449 people in the second group, 358 people, or 5%, developed dementia. Of the 7,312 people in the third group, 310, or 4%, developed dementia. Of the 2,117 people in the fourth group, 73 people, or 3%, developed dementia.

The researchers also validated their results in another dataset comprised of 68,200 older people from the U.K. Among them, 2,778 people developed dementia over an average time of 12 years. They observed a consistent result which shows a 17% decreased risk of dementia with every doubling of triglycerides levels.

Researchers also found that higher triglycerides were also associated with slower decline in composite cognition, a combined result from tests of global function, psychomotor speed, language and executive function and memory over time.

“Future studies are needed to investigate whether specific components within triglycerides may promote better cognitive function, with the hope of developing new preventive strategies,” Zhou said.

A limitation of the study was researchers looked only at people 65 and older who had no cognitive issues initially, so the findings are not generalizable to other populations.

Reference:

Association Between Triglycerides and Risk of Dementia in Community-Dwelling Older Adults: A Prospective Cohort Study. Zhen Zhou, Joanne Ryan, Andrew M Tonkin, Sophia Zoungas, Paul Lacaze, Rory Wolfe, Suzanne G Orchard, Anne M Murray, John J Mcneil, Chenglong Yu, Gerald F Watts, Sultana Monira Hussain, Lawrence J Beilin, Michael Ernst, Nigel Stocks, Robyn L Woods, Chao Zhu, Christopher Reid, Raj C Shah, Trevor T Chong, Ajay Sood, Kerry M Sheets, Mark Nelson. Neurology Oct 2023, 10.1212/WNL.0000000000207923; DOI: 10.1212/WNL.0000000000207923

Tags:    
Article Source : Neurology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News